Prevent Blindness launches ROP Awareness Week with education and support resources


The Retinopathy of Prematurity (ROP) Education and Support Programme is part of ROP Awareness Week, recognised from 26 February to 3 March

A newborn baby in an incubator. Image credit: ©Martin Valigursky –

Free resources from Prevent Blindness aim to aid in the detection and treatment of ROP. Image credit: ©Martin Valigursky –

Nonprofit Prevent Blindness has launched a new Retinopathy of Prematurity (ROP) Education and Support Programme as part of its ROP Awareness Week, recognised from 26 February to 3 March. According to a news release, this is the first ROP awareness week declared by the organisation, with the programme offering free educational resources for both parents and eye care professionals.

“Diagnosing and treating ROP early is essential for preventing or lessening ROP-associated vision loss,” said Jeff Todd, Prevent Blindness president and CEO, in the news release. “The ultimate goal for our new ROP programme is to educate and offer much-needed resources for families of children with ROP and support the healthcare professionals who care for premature children to help prevent unnecessary vision impairment.”

Prevent Blindness developed a specific website on ROP for the programme, which includes a general overview of the disease, how it is diagnosed and treated, how ROP affects a child throughout their life and supportive resources for families of children with ROP. Information was compiled for the website through partnerships with organisations like Hand to Hold, the National Coalition for Infant Health, and the SPAN Parent Advocacy Network to develop its resources.1

Other resources available through ROP Awareness Week include fact sheets, social media graphics in English and Spanish, online resources and a roundtable video series. These can be found on the Prevent Blindness website.1

ROP prevalence and developments

Over the past decade, pre- and early-term birth rates have dramatically risen, which makes infants more predisposed to developing ROP. From 2014 to 2022, preterm birth rate, or delivery before 37 weeks of pregnancy, rose 12% and early-term birth (37 to 38 weeks of pregnancy) rose 20%.2

A study from 2023 reviewed recent trends of ROP, citing the disease as the leading preventable cause of blindness and visual impairment in infants and young children. The researchers, led by first author Laura Bujoreanu Bezman, stated that screening and monitoring oxygen intake play a vital role in detection and treatment. They also attributed the increased prevalence of ROP to the improved survival rate of micro-premature babies, who are more likely to develop the condition.3

“Apart from [birth weight,] [gestational age,] and oxygen therapy, certain biological parameters can indicate the risk of ROP occurrence. IGF-1 plays an important part in the development of this pathology, and several studies have been sustaining lately that the intravenous therapy with Recombinant Human Insulan-Like Growth Factor (rhIGF-1) together with its binding protein -3 (rhIGFBP-3) is a promsing solution to normalise the plasmatic value of IGF-1 from the first phase of ROP. Starting from the idea that the kidneys and the retina have a similar embryological development, there have been recent reports to indicate a new potential risk factor, ie proteinuria” the authors said.

Risk factors to the progression of ROP can also be caused by central nervous system injuries, including intraventricular hemorrhage and periventricular leikomalacia.3


  1. Prevent Blindness launches new “Retinopathy of Prematurity (ROP) Education and Support Program” as part of inaugural ROP Awareness Week, Feb. 26 – March 3, 2024. Prevent Blindness. News Release. Published February 21, 2024. Accessed February 22, 2024.
  2. Martin JA, Osterman MJK. Shifts in the Distribution of Births by Gestational Age: United States, 2014-2022. Nat Vit Stat Reports. 2024;73:1-11.
  3. Bezman LB, Tiutiuca C, Totolici G, et al. Latest Trends in Retinopathy of Prematurity: Research on Risk Factors, Diagnostic Methods and Therapies. Int J Gen Med. 2023;16:937–949. doi: 10.2147/IJGM.S401122
Related Videos
Josefina Botta, MD, MSc, at ASCRS 2024
Dr Nir Shoham Hazon, Director, Miramichi EyeNB Centre of Excellence, New Brunswick, Canada
J. Morgan Micheletti, MD, speaks at the 2024 ASCRS meeting
Dr William Wiley of Cleveland Eye Clinic, Northeast Ohio
© 2024 MJH Life Sciences

All rights reserved.